• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, January 14, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Can we cure cancer by finding out how two proteins interact?

Bioengineer by Bioengineer
April 30, 2019
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

ISTANBUL, TURKEY – In a paper published in the Journal of Biological Chemistry, Dr. Özdemir has studied two protein families named Rho GTPases and IQGAPs, which are known to play an important role in cancer metastasis. These two “suspicious” protein families have been studied by many researchers over the years, but the interaction between them had not previously been fully understood.

It is important to understand how metastasis, the spreading of cancer from its primary site to other organs, takes place, since preventing metastasis means keeping cancer under control. This is why Dr. Özdemir chose to study these proteins, which are known to activate metastasis.

Requiring a large amount of probabilistic calculation, the study was only made possible through computational simulation techniques with the help of very powerful computers. A simulation environment in which many such elements as the water density in the cell, the ions and the three-dimensional structure of the proteins were very precisely simulated. This made it possible to observe how exactly the two proteins interacted, the points at which they bound, and what morphological changes the bonding caused in the proteins.

The simulation of the structures that included the numerous bonding points to find the correct bonding took six months. The study observed how bonding points and sequence of the two proteins, and how the large protein found its match and how the two complex structures bound together. And it was established that the complex structures that formed, activated the mechanisms which triggered metastasis in cells.

Dr. S?la Özdemir’s study was tested and replicated on cancer cells in a laboratory setting by another research group at the National Institutes of Health in the United States (NIH), and the results showed an exact match: The experiment verified the data produced through the computer simulations. The most important outcome of this discovery will be its contribution towards the design of a drug that targets the mechanism in question.

Following its publication in the Journal of Biological Chemistry, among the most prestigious journals in the field, Dr. Özdemir’s research went on to be published as part of a special collection by the journal of the most influential papers of 2018.

To view the video, please go to https://www.dropbox.com/s/nvbkr7cuggbn4x5/cdcgrdace_center.mp4?dl=0

###

Media Contact
Hande Sarantopoulos
[email protected]

Tags: BiochemistryBiomedical/Environmental/Chemical EngineeringBiotechnologycancerMedicine/Health
Share18Tweet8Share2ShareShareShare2

Related Posts

Psycho-Oncologists: Key Indicators of Patient Distress

January 13, 2026

METTL14-Regulated miR-101-3p Boosts NSCLC Drug Sensitivity

January 13, 2026

Carvacrol and Chloroquine Synergistically Halt Melanoma Metastasis

January 13, 2026

Venetoclax plus ML385 defeats AML chemotherapy resistance

January 13, 2026
Please login to join discussion

POPULAR NEWS

  • Enhancing Spiritual Care Education in Nursing Programs

    155 shares
    Share 62 Tweet 39
  • PTSD, Depression, Anxiety in Childhood Cancer Survivors, Parents

    147 shares
    Share 59 Tweet 37
  • Robotic Ureteral Reconstruction: A Novel Approach

    74 shares
    Share 30 Tweet 19
  • Study Reveals Lipid Accumulation in ME/CFS Cells

    53 shares
    Share 21 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

6-Phosphogluconate Dehydrogenase Drives Tumor Immune Suppression

Nonlinear X-Ray Four-Photon Interaction Unveiled

Multi-Omics Reveal Personalized Prognosis in Thyroid Cancer

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 71 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.